Ackler et al. (2010) proposed that the upregulation of BCL-2 and BCL-XL in targeted tumor lines has developed resistance toward the common cytotoxicity agents in which the sensitivity could be restored in the presence of navitoclax. This evidence concerns the gene BCL2L1 and neoplasm.